MARKET

BPTH

BPTH

Bio Path Hldg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.78
-0.09
-0.83%
Opening 12:52 11/14 EST
OPEN
10.96
PREV CLOSE
10.87
HIGH
10.96
LOW
10.75
VOLUME
6.44K
TURNOVER
--
52 WEEK HIGH
73.52
52 WEEK LOW
1.610
MARKET CAP
31.09M
P/E (TTM)
-1.0849
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BPTH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BPTH News

  • Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019
  • GlobeNewswire.6d ago
  • Investors Who Bought Bio-Path Holdings (NASDAQ:BPTH) Shares Five Years Ago Are Now Down 98%
  • Simply Wall St..10/29 11:47
  • Houston biotech co. avoids stock exchange delisting amid board shakeup
  • American City Business Journals.10/16 19:29
  • Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors
  • GlobeNewswire.10/15 13:00

More

Industry

Biotechnology & Medical Research
-0.08%
Pharmaceuticals & Medical Research
-0.45%

Hot Stocks

Name
Price
%Change

About BPTH

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
More

Webull offers Bio-Path Holdings Inc (BPTH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.